Report of Foreign Issuer (6-k)
November 08 2019 - 01:38PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November, 2019
Commission File
Number 001-15170
GlaxoSmithKline
plc
(Translation of
registrant's name into English)
980
Great West Road, Brentford, Middlesex, TW8 9GS
(Address of
principal executive office)
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline
plc (the 'Company')
Transaction
notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mrs
S Jackson
|
b)
|
Position/status
|
SVP,
Global Communications & CEO Office
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the transaction
|
The
sale of 1,158 Ordinary Shares, at a price of £17.2835 pursuant to a
transfer into an ISA.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2835
|
1,158
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A
(single transaction)
|
e)
|
Date
of the transaction
|
2019-11-08
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mrs
S Jackson
|
b)
|
Position/status
|
SVP,
Global Communications & CEO Office
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the transaction
|
The
repurchase of 1,149 Ordinary Shares, at a price of £17.2937, to
implement a transfer into an ISA.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2937
|
1,149
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A
(single transaction)
|
e)
|
Date
of the transaction
|
2019-11-08
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr
D Jackson
|
b)
|
Position/status
|
PCA
of Mrs S Jackson (SVP, Global Communications & CEO
Office)
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the transaction
|
The
sale of 1,158 Ordinary Shares at a price of £17.2935 pursuant to a
transfer into an ISA.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2935
|
1,158
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A
(single transaction)
|
e)
|
Date
of the transaction
|
2019-11-08
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr
D Jackson
|
b)
|
Position/status
|
PCA
of Mrs S Jackson (SVP, Global Communications & CEO
Office)
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline
plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description of the financial
instrument
|
Ordinary
shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
b)
|
Nature of the transaction
|
The
repurchase of 1,150 Ordinary Shares at a price of £17.2905 to
implement a transfer into an ISA.
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£17.2905
|
1,150
|
d)
|
Aggregated information
Aggregated volume Price
|
N/A
(single transaction)
|
e)
|
Date
of the transaction
|
2019-11-08
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
GlaxoSmithKline
plc
|
|
(Registrant)
|
|
|
Date: November
08, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart
From Dec 2020 to Jan 2021
GlaxoSmithKline (NYSE:GSK)
Historical Stock Chart
From Jan 2020 to Jan 2021